Get the latest news, insights, and market updates on CHRS (Coherus Oncology, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks
The latest update on Coherus Oncology keeps the model fair value anchored at US$6.75, with no change to the prior price target. Analysts are split on the outlook, with bullish voices arguing that current ratings and fresh Outperform calls suggest the US$6.75 level already captures more cautious assumptions. In contrast, more cautious views question how firmly that target can hold if execution slips. As you read on, you will see how to track these shifting views and what to watch as the story... Mar 5, 2026 - $CHRS
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following t Mar 2, 2026 - $CHRS
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days. 46th Annual TD Cowen Healthc Feb 23, 2026 - $CHRS
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS)
Coherus Oncology just saw its fair value estimate move from US$5.67 to US$6.75, as analysts refreshed their models around upcoming clinical readouts and recent corporate updates. At the same time, the implied revenue trend was reset from a 20.31% decline to a 13.53% decline, with a slightly higher discount rate of about 7.40% now used to reflect a modestly higher required return on the stock. Continue with this article to see how you can keep on top of these shifting assumptions and the... Feb 18, 2026 - $CHRS
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwrit Feb 17, 2026 - $CHRS
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offe Feb 13, 2026 - $CHRS
Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -0.74% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 12, 2026 - $CHRS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple